Knee cartilage has no blood supply. That single biological fact is why, for decades, orthopedic medicine has operated under one blunt assumption: once it’s gone, it’s gone. The body can’t deliver the repair signals that blood-rich tissue receives after injury. Cartilage just wears down, silently, until the pain becomes impossible to ignore.
That assumption now has a serious challenger – and it didn’t come from a stem cell lab or a surgical technique. It came from a protein most people have never heard of.
A study published in the journal Science, by researchers at Stanford Medicine, found that blocking a single aging-related protein called 15-PGDH not only restored lost cartilage in the knee joints of old mice, but also triggered cartilage regeneration in human tissue samples – tissue that had already deteriorated to the point of requiring joint replacement surgery. The mechanism behind it rewrites a fundamental assumption about how cartilage works, and why aging joints can’t fix themselves.
The Protein That Puts Repair on Pause
15-PGDH is a “gerozyme” – a protein whose levels increase with age and suppress the body’s tissue repair capacity. The word “gerozyme” itself is recent: the concept was developed by the same Stanford research team, and their new work found a way to regenerate worn-out joint cartilage by blocking this aging-related protein. Scientists at Stanford Medicine discovered a treatment that can reverse cartilage loss in aging joints and even prevent arthritis after knee injuries, with the therapy restoring healthy, shock-absorbing cartilage in old mice and injured joints, dramatically improving movement and joint function.
What makes 15-PGDH particularly relevant to aging joints is how dramatically its levels shift over time. ScienceDaily’s coverage of the study noted that 15-PGDH levels roughly doubled with age in mouse knee cartilage. As that protein accumulates, it effectively applies a brake to the body’s natural repair machinery – and the brake gets harder and harder to release.
The findings were led by Dr. Helen Blau, director of the Baxter Laboratory for Stem Cell Biology at Stanford University School of Medicine, and Dr. Nidhi Bhutani, professor of orthopedic surgery at Stanford. Their central finding is that 15-PGDH, which increases with age across multiple tissues, acts as a biological brake on the body’s ability to regenerate cartilage.
How Blocking It Actually Works
The mechanism is where this research gets genuinely surprising. For most tissues in the body, regeneration happens the way you’d expect: stem cells multiply and develop into new specialized cells. Cartilage appears to work differently. Instead of relying on stem cells, cartilage-producing cells called chondrocytes seem able to shift their gene activity and return to a more youthful state.
The cells needed to rebuild cartilage are already sitting inside the joint – they just need the suppression lifted.
As Dr. Blau described it: “This is a new way of regenerating adult tissue. We were looking for stem cells, but they are clearly not involved. It’s very exciting.”
The mechanism involves prostaglandin E2, a signaling molecule. When 15-PGDH is blocked, prostaglandin E2 levels rise, and that rise appears to prompt chondrocytes to shift into repair mode. The effect on cell populations was dramatic. A treatment that targets a protein linked to aging restored lost knee cartilage in older mice and prevented arthritis from developing after serious joint injuries. Researchers also found encouraging results in human tissue – samples collected during knee replacement surgeries began producing new, functional cartilage when exposed to the treatment.
The specific cellular numbers bear closer examination. Researchers found that the population of cartilage-degrading chondrocytes dropped from 8% of cells to 3% after treatment, while a separate population involved in hyaline cartilage formation increased from 22% to 42%.
The cartilage that grew back wasn’t an inferior substitute. The study in Science confirmed that the regenerated tissue was hyaline articular cartilage – the high-quality, load-bearing type – not functionally inferior fibrocartilage, and that the new tissue showed proper collagen II and proteoglycan synthesis. Fibrocartilage, which often forms after injury, lacks the mechanical properties needed to cushion a joint effectively over decades of use.
Treated mice also had a steadier gait and were observed to place more weight on their injured legs – signs that the cartilage restoration improved physical function. Pain measurements supported this. The study found that pain, the most common symptom of osteoarthritis, was reduced across three well-established pain assessment tests in the treated animals.
Why This Matters So Much Right Now
According to the CDC, 1 in 5 U.S. adults – approximately 53.2 million people – has some form of arthritis. Osteoarthritis is the most common form, affecting 32.5 million Americans. Globally, the picture is similarly stark: a 2025 study in Arthritis Research & Therapy found that in 2021, osteoarthritis affected an estimated 607 million people worldwide. The numbers are climbing. The CDC projects that by 2040, approximately 78 million Americans will be living with arthritis.
The reason the Stanford findings carry such weight is not just scientific novelty. There is currently no drug that can regenerate cartilage, no injection that can reverse osteoarthritis. Joint replacement – with all its surgical risk, recovery time, and limited lifespan – is the end of the road for most patients.
No existing FDA-approved drug can slow or reverse cartilage loss. All current treatments manage symptoms or replace damaged joints. Pain medication, physical therapy, corticosteroid injections, hyaluronic acid injections – all of these address how the joint feels, not what’s actually happening to the tissue inside it. The Stanford approach is the first to demonstrate actual biological reversal in both aging animal models and human tissue.
Researchers also tested the treatment in a scenario that mirrors one of the most common sports injuries: ACL tears. The treatment prevented arthritis from developing after serious joint injuries, mimicking the ACL tears often experienced by athletes. That finding opens up a second potential use case beyond age-related osteoarthritis: early intervention after joint injury, before the damage has time to progress.
The Human Tissue Evidence
The study’s most striking data point may be what happened when researchers applied the 15-PGDH inhibitor to human tissue. These weren’t samples from mildly affected joints. The human cartilage samples came from knee replacement surgeries – tissue so degenerated that surgical removal was already necessary – and that tissue began forming new cartilage when exposed to the 15-PGDH inhibitor in laboratory experiments.
Animal studies routinely demonstrate effects that fail to translate to human biology. The fact that ex vivo (meaning outside the body, in a lab setting) human cartilage responded to the treatment provides a meaningful early signal that the mechanism isn’t species-specific. It also raises the possibility that severely damaged joints – not just early-stage ones – could eventually be candidates for this therapy.
How Close Is This to a Clinic?
The findings raise the possibility that damaged cartilage caused by aging or osteoarthritis could one day be repaired with either a local injection or an oral medication. If successful in people, the approach could reduce the need for knee and hip replacement surgeries.
One significant advantage the researchers have is prior safety data. An oral version of the treatment is already being tested in clinical trials for age-related muscle weakness – a separate condition the same research group has studied. The small-molecule inhibitor has already cleared Phase 1 safety testing for that condition, providing a potential faster path to human trials for joint applications.
A compound with an existing clean Phase 1 safety profile faces a less uncertain path through the trial process than a completely novel agent. Human cartilage inside a living, weight-bearing joint is a far more complex environment than a lab dish, so success in the current data does not guarantee success in an arthritis trial – but it removes one of the biggest early hurdles.
It’s also worth noting the financial interests involved: Blau, Bhutani, and several co-authors are inventors on patent applications held by Stanford University related to 15-PGDH inhibition in cartilage, which are licensed to Epirium Bio. Blau is a co-founder of Epirium and holds equity in the company. That doesn’t invalidate the science, but it’s standard practice to flag it when assessing a study’s independent standing.
What to Do Now
The treatment isn’t available to patients yet. There is no pill, no injection, and no supplement currently on the market that targets 15-PGDH in a clinically meaningful way. Anyone claiming otherwise is selling something the research doesn’t support. Clinical trials for joint applications are the next step, and those take years.
Read More: Is Semaglutide the Future of Arthritis Treatment?
What This Means for You
Cartilage-producing cells in an aging or damaged joint can shift their gene activity and return to a more functional state. They don’t need to be replaced with new cellular machinery – they need the blocking signal removed. That reframes what “treating arthritis” could eventually look like: not replacing a joint, but unlocking the joint’s existing repair capacity.
For the tens of millions of Americans currently managing osteoarthritis with pain medication and cortisone shots, this research doesn’t offer anything to take home today. What it does close is the door on one long-standing assumption – that the worn-out joint is simply a biological dead end. The cells needed to rebuild cartilage are already there. If the clinical trials go well, the option to reverse arthritis cartilage loss rather than simply manage its symptoms could arrive within the decade. That’s a different kind of conversation to be having with your orthopedic surgeon. In the meantime, managing joint inflammation through diet and lifestyle remains the most evidence-backed tool available for slowing disease progression while the science catches up.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.